CoChat

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Open access
Cole, Tracy A., Zhao, Hien, Collier, Timothy J., Sandoval, Ivette, Sortwell, Caryl E., Steece-Collier, Kathy, Daley, Brian F., Booms, Alix, Lipton, Jack, Welch, Mackenzie, Berman, Melissa, Jandreski, Luke, Graham, Danielle, Weihofen, Andreas, Celano, Stephanie, Schulz, Emily, Cole-Strauss, Allyson, Luna, Esteban, Quach, Duc, Mohan, Apoorva, Bennett, C. Frank, Swayze, Eric E., Kordasiewicz, Holly B., Luk, Kelvin C., Paumier, Katrina L. · 2021 · JCI Insight
Cited by 151

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Parkinson's disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding α-synuclein (aSyn) protein, either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent preformed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA-targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the nonhuman primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that, by inhibiting production of aSyn, it may be possible to reverse established pathology; thus, these data support the development of SNCA ASOs as a potential disease-modifying therapy for PD and related synucleinopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.135633

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 151

Metadata

Authors
Cole, T. A., Zhao, H., Collier, T. J., Sandoval, I., Sortwell, C. E., Steece-Collier, K., Daley, B. F., Booms, A., Lipton, J., Welch, M., Berman, M., Jandreski, L., Graham, D., Weihofen, A., Celano, S., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., Mohan, A., Bennett, C. F., Swayze, E. E., Kordasiewicz, H. B., Luk, K. C., & Paumier, K. L.
Venue
JCI Insight
Published
2021-03-08
Volume
6
Issue
5
ISSN
2379-3708 (ISSN-L)
OpenAlex
W3133927909
Cited by
151
References
25
FWCI
8.96
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. https://app.cochat.ai/papers/10.1172/jci.insight.135633
The paper
Cole, T. A., Zhao, H., Collier, T. J., Sandoval, I., Sortwell, C. E., Steece-Collier, K., Daley, B. F., Booms, A., Lipton, J., Welch, M., Berman, M., Jandreski, L., Graham, D., Weihofen, A., Celano, S., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., . . . Paumier, K. L. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight. https://doi.org/10.1172/jci.insight.135633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.